# Allergy Therapeutics Plc, Mi-Pay Group PLC, Vipera PLC Notice of Results

- Link: https://www.directorstalkinterviews.com/allergy-therapeutics-plc-mi-pay-group-plc-vipera-plc-notice-results/412733645
- Published: 2017-08-15T07:09:55+01:00
- Author: Giles Arbor

**Allergy Therapeutics Plc** ([LON:AGY](https://www.directorstalkinterviews.com/company/allergy-therapeutics/agy.l)),
the fully integrated specialty pharmaceutical group specialising in allergy vaccines,
will issue its preliminary results for the year ended 30 June 2017 on Thursday 28
September 2017. Manuel Llobet, Chief Executive Officer, and Nick Wykeman, Finance
Director, will hold a presentation and conference call for analysts on the day of
results at 9:30am BST at The Dome Room, 1 Cornhill, London, EC3V 3ND.

**Mi-Pay Plc** (LON:MPAY), the leading provider of mobile payment solutions to Tier
1 Mobile Network Operators and Mobile Virtual Network Operators, will be announcing
its Interim Results for the six months ended 30 June 2017, on Tuesday 26th September
2017. Management will be hosting a presentation for analysts on the day of results
at 11:00am at 1 King Street, London, EC2V 8AU. Analysts who wish to attend should
register their interest with Heather Armstrong contactable at heather.armstrong@
investor-focus.co.uk or 0203 053 8671.

**Vipera Plc** (LON:VIP), the specialist provider of mobile financial services, 
will be announcing its half year results for the six-month period ended 30 June 
2017, on the 5 September 2017. The management will be hosting a presentation for
analysts on the day of results at 11:00am at the offices of finnCap, 60 New Broad
Street, London, EC2M 1JJ. Analysts who wish to attend the presentation should register
their interest with Heather Armstrong at heather.armstrong@investor-focus.co.uk 
or 020 3053 8671.

 

Allergy Therapeutics is an international specialty pharmaceutical group focussed
on the treatment and diagnosis of allergic disorders including immunotherapy vaccines
that have the potential to cure disease. The Group sells proprietary products and
third party products from its subsidiaries in nine major European countries and 
via distribution agreements in an additional ten countries. Its broad pipeline of
products in clinical development include vaccines for grass, tree and house dust
mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to
boost performance of vaccines outside allergy are also in development.

Founded in 2003, Mi-Pay Group delivers fully outsourced online and related payment
solutions to digital ecommerce clients, primarily in the mobile sector. Its product
offering provides the infrastructure to enable pre-paid mobile devices to be topped
up via a variety of channels such as websites, mobile applications and social media
applications and customers include Mobile Network Operators (MNOs) and Mobile Virtual
Network Operators (MVNOs). Mi-Pay sells, integrates and operates its products and
solutions on a global basis. For further information, please visit www.Mi-Pay.com
or contact details as shown above.

Vipera Plc a cutting edge Mobile Financial Services and Digital Customer Engagement
Solutions provider, serves financial institutions worldwide with differentiated 
mobile banking, card management and customer engagement capabilities based around
its proprietary bank grade multi-purpose platform, Motif. Additionally, it provides
consultancy and other services to banks and financial institutions.

Share on: